cis-4-methylcyclohexanamine hydrochloride | 33483-66-8

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: cis-4-methylcyclohexanamine hydrochloride
• CAS: 33483-66-8
• 化学式: C₇H₁₅N*ClH
• 分子量: 149.664
• InChiKey: GIRKJSRZELQHDX-UKMDXRBESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.95
• 重原子数：
  9.0
• 可旋转键数：
  0.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26.02
• 氢给体数：
  1.0
• 氢受体数：
  1.0

安全信息

• 海关编码：
  2921300090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  cis-4-methylcyclohexanamine hydrochloride 在 三乙胺 、 sodium nitrite 作用下， 以 甲酸 为溶剂， 生成 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea
  参考文献：
  名称：

  合成潜在的抗癌药。38. N-亚硝基脲。4.卤代乙基衍生物的进一步合成和评价。

  摘要：

  DOI：

  10.1021/jm00289a011
• 作为产物：
  描述：

  4-甲基环己酮 在 palladium 10% on activated carbon 、 甲酸铵 、 盐酸 作用下， 以 甲醇 为溶剂， 生成 trans-4-Methylcyclohexylamine hydrochloride 、 cis-4-methylcyclohexanamine hydrochloride
  参考文献：
  名称：

  [EN] PROCESS TO PRODUCE (1r,4r)-4-SUBSTITUTED CYCLOHEXANE-1-AMINES
  [FR] PROCÉDÉ DE PRODUCTION DE CYCLOHEXANE-1-AMINES À SUBSTITUTION (1 R,4 R)-4

  摘要：

  The invention relates to a process to produce a (1r,4r)-4-substituted cyclohexane-1-amine [further referred astrans-4-substituted cyclohexane-1-amine] of formula (T), starting from a diastereomeric mixture of 4-substituted cyclohexane-1-amines (formula (C) + formula (T)) or any salt of them by using a single transaminase biocatalyst in whole-cell, soluble or immobilized form in the presence of an amine acceptor used in sub-equimolar up to equimolar quantities in batch mode or in continuous-flow mode. In the first aspect of the present invention 2-(trans-4-aminocyclohexyl)acetic acid esters, more preferably a C1-6alkyl esters, particularly 2-(trans-4-aminocyclohexyl)acetic acid ethyl ester may be produced. In the second aspect of the present invention hydroxyl-protected or protective group-freetrans-4-(2-hydroxyethyl)cyclohexan-1-amines, particularlytrans-4-(2-hydroxyethyl)cyclohexan-1-amine may be produced. In the third aspect of the present invention protected 2-(trans-4-aminocyclohexyl)acetaldehydes, particularlytrans-4-((1,3-dioxolan-2-yl)methyl)cyclohexan-1-amine may be produced.

  公开号：

  WO2023042081A1

文献信息

• Compound and use of the same as medicine
  申请人：Tsumura & Co.

  公开号：US05344845A1

  公开（公告）日：1994-09-06

  Disclosed herein is a specific cinnamic acid derivative such as methyl 4-(4-acetoxy-3-methoxycinnamanide)-1-cyclohexanecarboxylate, or a pharmaceutically acceptable salt thereof. These compounds are useful as IV-type allergic reaction-suppressive drugs.

  本文揭示了一种特定的肉桂酸衍生物，例如甲基4-(4-乙酰氧基-3-甲氧基肉桂酰胺)-1-环己烷羧酸酯或其药学上可接受的盐。这些化合物可用作IV型过敏反应抑制药物。
• Pyrimidine Compounds and Methods of Making and Using Same
  申请人：Chiang Phoebe

  公开号：US20110281873A1

  公开（公告）日：2011-11-17

  Disclosed herein are pyrimidinyl compounds that are contemplated to be modulators of cystic fibrosis transmembrane regulators (CFTR), and methods of making and using same. Also provided are pharmaceutical compositions and methods of treating disorders associated with cystic fibrosis transmembrane regulators, such as airway inflammation, cystic fibrosis, and the like.

  本文披露了嘧啶基化合物，被认为是囊性纤维化跨膜调节器（CFTR）的调节剂，并提供了制备和使用它们的方法。还提供了药物组合物和治疗与囊性纤维化跨膜调节器相关的疾病的方法，例如气道炎症，囊性纤维化等。
• Cycloalkyl-Substituted Imidazole Derivative
  申请人：Nagata Tsutomu

  公开号：US20130022587A1

  公开（公告）日：2013-01-24

  A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R 1 , R 2 , and R 3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R 4 represents a hydrogen atom or a prodrug group; and Y represents —CH 2 —CHR 5 —CH 2 —NHR 6 (wherein R 5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R 6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

  以下是通式（I）所代表的化合物或其药学上可接受的盐，其中A代表一个C3到C12的环烷基，该环烷基可以被一个到三个选自氟基、羟基、C1到C6烷基等的基团所取代；R1、R2和R3各自独立地代表氢原子、氟基或C1到C6烷基；R4代表氢原子或前药基团；Y代表—CH2—CHR5— —NHR6（其中R5代表氢原子、C1到C6烷基或C1到C6烷氧基，R6代表氢原子或前药基团）等，具有极好的TAFIa抑制活性，是治疗心肌梗死、心绞痛、急性冠状动脉综合征、脑梗死、深静脉血栓形成、肺栓塞等疾病的治疗药物。
• Pyrimidine compounds and methods of making and using same
  申请人：Cystic Fibrosis Foundation Therapeutics, Inc.

  公开号：US08334292B1

  公开（公告）日：2012-12-18

  Disclosed herein are pyrimidinyl compounds that are contemplated to be modulators of cystic fibrosis transmembrane regulators (CFTR), and methods of making and using same. Also provided are pharmaceutical compositions and methods of treating disorders associated with cystic fibrosis transmembrane regulators, such as airway inflammation, cystic fibrosis, and the like.

  本文披露了嘧啶基化合物，这些化合物被认为是囊性纤维化跨膜调节因子（CFTR）的调节剂，以及制备和使用它们的方法。还提供了制药组合物和治疗与囊性纤维化跨膜调节因子相关的疾病的方法，例如气道炎症、囊性纤维化等。
• NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE
  申请人：TSUMURA & CO.

  公开号：EP0535250A1

  公开（公告）日：1993-04-07

  Specified cinnamic acid derivatives, such as methyl 4-(4-acetoxy-3-methoxycinnamamide)-1-methyl-1-cyclohexanecarboxylate, and pharmaceutically acceptable salts thereof, which are useful as an allergy type IV reaction inhibitor.

  特定肉桂酸衍生物，如 4-(4-乙酰氧基-3-甲氧基肉桂酰胺)-1-甲基-1-环己烷羧酸甲酯及其药学上可接受的盐，可用作 IV 型过敏反应抑制剂。